Development of R 8 modified epirubicin–dihydroartemisinin liposomes for treatment of non-small-cell lung cancer
Source abstract
Abstract
Presently, there are no few anticancer drugs that have been used clinically due to their poor targeting ability, short half-life period, non-selective distributions, generation of vasculogenic mimicry (VM) channels, high metastasis, and high recurrence rate. This study aimed to explore the effects of R8 modified epirubicin-dihydroartemisinin liposomes that could target non-small-cell lung cancer (NSCLC) cells, destroy VM channels, inhibit tumor metastasis, and explain the possible underlying mechanism. In vitro assays indicated that R8 modified epirubicin-dihydroartemisinin liposomes with ideal physicochemical characteristics could exhibit not only powerful cytotoxicity on A549 cells, but also the effective suppression of VM channels and tumor metastasis. Mechanistic studies manifested that R8 modified epirubicin-dihydroartemisinin liposomes could down-regulate the levels of VE-Cad, TGF-β1, MMP-2, and HIF-1α. In vivo assays indicated that R8 modified epirubicin-dihydroartemisinin liposomes could both increase the selective accumulation of chemotherapeutic drugs at tumor sites and show a targeting conspicuous of antitumor efficacy. In conclusion, the R8 modified epirubicin-dihydroartemisinin liposomes prepared in this study provide a treatment strategy with high efficiency for NSCLC.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Peptidase Inhibition and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Liaoning University of Traditional Chinese Medicine
Linyi Food and Drug Testing Center
Department of Pharmaceutical Engineering, Beijing Institute of Petrochemical Technology
Funding
National Natural Science Foundation of China
References (42)
Show source-provided references
1. 10.3171/2018.10.JNS18137110.3171/2018.10.JNS181371 ↗
2. 10.1053/j.seminoncol.2016.07.00110.1053/j.seminoncol.2016.07.001 ↗
3. 10.1016/j.ctrv.2018.08.00210.1016/j.ctrv.2018.08.002 ↗
4. 10.1007/s00018-016-2346-310.1007/s00018-016-2346-3 ↗
5. 10.5306/wjco.v5.i2.10310.5306/wjco.v5.i2.103 ↗
6. 10.2147/IJN.S11983910.2147/IJN.S119839 ↗
7. 10.3109/21691401.2015.105246610.3109/21691401.2015.1052466 ↗
8. M, Li Z J, Lin Z, et al. Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer. Am J Cancer Res. 2018;8:2402–2418.
9. 10.1158/1078-0432.CCR-16-263310.1158/1078-0432.CCR-16-2633 ↗
10. 10.1159/00048787210.1159/000487872 ↗
11. 10.1002/advs.20160022910.1002/advs.201600229 ↗
12. 10.1038/s41467-018-07308-510.1038/s41467-018-07308-5 ↗
13. 10.1038/s41416-018-0033-x10.1038/s41416-018-0033-x ↗
14. 10.1038/ncomms1115010.1038/ncomms11150 ↗
15. 10.1080/21691401.2018.148108210.1080/21691401.2018.1481082 ↗
16. Liu JY, Wu XY, Wu GN, et al. FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma. Am J Transl Res. 2017;9:2207–2218.
17. 10.1016/j.jconrel.2018.10.03510.1016/j.jconrel.2018.10.035 ↗
18. 10.1016/j.ijpharm.2017.03.03410.1016/j.ijpharm.2017.03.034 ↗
19. 10.1002/jcp.2542610.1002/jcp.25426 ↗
20. 10.3892/ol.2014.191810.3892/ol.2014.1918 ↗
21. 10.1002/cam4.182710.1002/cam4.1827 ↗
22. Zheng C, Ma C, Bai E, et al. Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma . Int J Clin Exp Med. 2015;8:1658
23. 10.1016/j.biomaterials.2014.02.03110.1016/j.biomaterials.2014.02.031 ↗
24. 10.1248/bpb.b17-0084810.1248/bpb.b17-00848 ↗
25. 10.2174/092986732466617100912015410.2174/0929867324666171009120154 ↗
26. 10.1016/j.ejps.2016.09.02410.1016/j.ejps.2016.09.024 ↗
27. 10.1111/cas.1381810.1111/cas.13818 ↗
28. 10.1080/10717544.2018.143609710.1080/10717544.2018.1436097 ↗
29. 10.18632/oncotarget.226710.18632/oncotarget.2267 ↗
30. 10.1080/21691401.2018.143318710.1080/21691401.2018.1433187 ↗
31. Zhao MH, Yuan L, Meng LY, et al. Quercetin-loaded mixed micelles exhibit enhanced cytotoxic efficacy in non-small cell lung cancer in vitro. Exp Therap Med. 2017;14:5503–5508.
32. 10.2147/IJN.S14178710.2147/IJN.S141787 ↗
33. 10.1166/jnn.2018.1544710.1166/jnn.2018.15447 ↗
34. 10.1080/10717544.2018.143574710.1080/10717544.2018.1435747 ↗
35. 10.18632/oncotarget.2321910.18632/oncotarget.23219 ↗
36. 10.1016/j.ejps.2017.06.00210.1016/j.ejps.2017.06.002 ↗
37. 10.3858/emm.2008.40.6.61710.3858/emm.2008.40.6.617 ↗
38. 10.1016/j.intimp.2017.05.01410.1016/j.intimp.2017.05.014 ↗
39. 10.1016/j.cbi.2017.03.00510.1016/j.cbi.2017.03.005 ↗
40. 10.2147/IJN.S12266610.2147/IJN.S122666 ↗
41. 10.18632/oncotarget.2150810.18632/oncotarget.21508 ↗
42. 10.1080/21691401.2016.120225710.1080/21691401.2016.1202257 ↗